Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.55
$0.09(6.34%)
At close: 4:00 PM EDT
$1.55
$0.09(6.34%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume230.62K
Average Volume (3M)8.48M
Market Cap
$770.97M
Enterprise Value$807.52M
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume5,964,227
30 Day Avg. Volume8,483,367
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit4.74
Enterprise Value/Ebitda-19.52
Forecast
1Y Price Target
$4.33Price Target Upside179.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$236.29M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthSustained growth in RYTELO revenue and management’s guidance indicate expanding commercial adoption rather than a single-period contribution. Continued account and patient-start growth could broaden the product’s revenue base and improve operating leverage as commercialization scales.
Operating Expense DisciplineExpenses growing more slowly than revenue demonstrates improving operating leverage despite continued commercial and clinical investment. If this discipline persists, it can narrow operating losses, extend available funding, and increase the long-term earnings potential of the commercial platform.
Improved Capital StructureThe sharp reduction in leverage leaves Geron with a materially cleaner capital structure than the prior year. Lower debt exposure should reduce financial pressure and preserve greater flexibility to fund RYTELO commercialization and clinical programs while revenue continues to develop.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not yet self-funding despite commercial revenue growth. Continued burn can consume cash reserves and may require external financing or other balance-sheet resources, creating dilution and execution pressure over the next several quarters.
Gross-to-Net PressureRising deductions reduce realized revenue per unit and can limit the benefit of reported prescription and demand growth. Persistent gross-to-net pressure would constrain margins, make revenue guidance harder to convert into cash generation, and increase the scale required to reach profitability.
Clinical And Regulatory UncertaintyPotential changes to the interim analysis design introduce uncertainty around the myelofibrosis program’s readout path and regulatory execution. Even with the base-case final analysis still targeted for H2 2028, evolving requirements could affect timing, evidence interpretation, and future investment needs.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $770.97M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 04, 2026 which is in 14 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 21.642%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (179.57% Upside)
$4.33 (179.57% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 19.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.36%
12-Months-Change
Fundamentals
Return on Equity
-30.31%
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$4.33
▲(179.57% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.32% Mutual Funds
0.34% Other Institutional Investors
72.81% Public Companies and
Individual Investors